Analyzing Cytokinetics (NASDAQ:CYTK) and Acumen Pharmaceuticals (NASDAQ:ABOS)

Cytokinetics (NASDAQ:CYTK) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Institutional and Insider Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Cytokinetics and Acumen Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	3	17	1	2.82
Acumen Pharmaceuticals	1	0	3	0	2.50

Cytokinetics currently has a consensus price target of $97.45, indicating a potential upside of 28.51%. Acumen Pharmaceuticals has a consensus price target of $6.67, indicating a potential upside of 153.97%. Given Acumen Pharmaceuticals’ higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than Cytokinetics.

Earnings & Valuation

This table compares Cytokinetics and Acumen Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	107.17	-$784.96 million	($6.84)	-11.09
Acumen Pharmaceuticals	N/A	N/A	-$121.33 million	($2.01)	-1.31

Acumen Pharmaceuticals has lower revenue, but higher earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cytokinetics and Acumen Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Acumen Pharmaceuticals	N/A	-111.26%	-75.67%

Volatility & Risk

Cytokinetics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the S&P 500.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.